GlassScriptPhysician profile
Charles Ruotolo
NPI 1255307443
$7,992.78
in general payments reported to CMS, 2019-2025
13 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,955 · 2020: $61.06 · 2021: $484 · 2022: $2,395 · 2023: $533 · 2024: $972 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gotham Surgical Solutions & Devices, INC. | $4,267.10 | 2019-2022 | |
| Depuy Synthes Sales INC. | $1,218.78 | 2019-2025 | Na, Crosstie, Motoband |
| Zimmer Biomet Holdings, INC. | $894.42 | 2019-2024 | Tapestry, Persona |
| Stryker Corporation | $870.53 | 2022-2025 | Mako |
| Vertex Pharmaceuticals Incorporated | $208.29 | 2024-2025 | |
| Bioventus LLC | $143.75 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
| Heraeus Medical, LLC. | $82.33 | 2022 | |
| Smith+Nephew, INC. | $79.95 | 2022 | |
| Medical Device Business Services, INC. | $60.00 | 2025 | Truespan Orthocord |
| Pacira Therapeutics, INC. | $56.06 | 2020-2021 | |
| Polaris Technology Solutions LLC | $44.28 | 2024-2025 | |
| Kerecis Limited | $33.76 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Forte Bio-Pharma LLC | $33.53 | 2024 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ruotolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.